Immunovant, Inc. (IMVT) [Rocket]

In millions, except per share items	Jun-30-23	Dec-31-22	Jun-30-22	Mar-31-22	Dec-31-21	Sep-30-21	Jun-30-21	Mar-31-21
	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K
Operating expenses:
Research and development			111.5	101.8	88.4	79.8	70.4	68.6
General and administrative			55.0	54.2	49.3	48.3	41.0	39.5
Total operating expenses			166.5	156.0	137.7	128.1	111.4	108.1
Other income			-1.9	-2.2	-0.6	-0.2	0.1	0.6
Loss before provision (benefit) for income taxes			-166.3	-156.8	-137.9	-128.6	-111.6	-81.1
Provision (benefit) for income taxes			0.3	-0.1		-0.5	-0.4	-0.4
Net loss			-166.6	-156.7	-137.7	-128.1	-111.2	-107.4

Net loss per common share - basic (in dollars per share)			($1.47)	($1.43)	($1.30)	($1.26)	($1.16)	($1.23)
Net loss per common share - diluted (in dollars per share)			($1.47)	($1.43)	($1.30)	($1.26)	($1.16)	($1.23)

Weighted-average common shares outstanding – basic (in shares)			112.6	107.9	102.5	98.2	92.0	85.2
Weighted-average common shares outstanding – diluted (in shares)			112.6	107.9	102.5	98.2	92.0	67.5